Azitra (AZTR) Share-based Compensation (2022 - 2026)
Azitra (AZTR) reported Share-based Compensation of $6149.0 for Q1 2026, down 79.77% on a YoY basis from $30402.0 in Q1 2025, and down 49.37% quarter-over-quarter from $12146.0 in Q4 2025.
Azitra (AZTR) Share-based Compensation (2022 - 2026) Analysis & Trends
Azitra has reported Share-based Compensation for 5 years, with the latest figure at $6149.0 in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation fell 79.77% year-over-year to $6149.0; the trailing twelve-month figure through Mar 2026 stood at $38491.0 (down 84.05% YoY), and the FY2025 full-year result was $62744.0, down 74.4% from the prior year.
- Share-based Compensation for Q1 2026 stood at $6149.0, down from $12146.0 in the prior quarter.
- The five-year high for Share-based Compensation was $143534.0 in Q3 2024, with the low at $4165.0 in Q3 2025.
- Historically, Share-based Compensation has averaged $35940.5 across 5 years, with a median of $34170.0 in 2024.
- Annual changes were most pronounced in 2024 — Share-based Compensation soared 267.34% — and 2025, when it slumped 97.1%.
- Azitra's Share-based Compensation stood at $29327.0 in 2022, then rose by 18.81% to $34844.0 in 2023, then declined by 4.78% to $33178.0 in 2024, then sank by 63.39% to $12146.0 in 2025, then slumped by 49.37% to $6149.0 in 2026.
- The last three Share-based Compensation figures came in at $6149.0 (Q1 2026), $12146.0 (Q4 2025), and $4165.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | 6,149.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,149.00 |
| Mar 31, 2026 | 6,149.00 |
| Dec 31, 2025 | 12,146.00 |
| Dec 31, 2025 | 12,146.00 |
| Sep 30, 2025 | 4,165.00 |
| Sep 30, 2025 | 4,165.00 |
| Jun 30, 2025 | 16,031.00 |
| Jun 30, 2025 | 16,031.00 |
| Mar 31, 2025 | 30,402.00 |
| Mar 31, 2025 | 30,402.00 |
| Dec 31, 2024 | 33,178.00 |
| Dec 31, 2024 | 33,178.00 |
| Sep 30, 2024 | 143,534.00 |
| Sep 30, 2024 | 143,534.00 |
| Jun 30, 2024 | 34,170.00 |
| Jun 30, 2024 | 34,170.00 |
| Mar 31, 2024 | 34,171.00 |
| Mar 31, 2024 | 34,171.00 |
| Dec 31, 2023 | 34,844.00 |
| Dec 31, 2023 | 34,844.00 |